Sure. My guesswork may be based on hope (isn't all investor guesswork). But yours is based on cynicism.
Yes. They are in Thailand because it's cheap. So is everyone else, because it's cheap.
The Gilead/India deal for Harvoni was struck after Biotron had designed and set the clinical trial protocols. Given the lead time in satisfying ethics and regulatory constraints in conducting clinical trials, it's not like they could suddenly change.
My earlier point also remains. A clinical trial based on a combined Harvoni/BIT225 treatment would not be useful in producing statistically/clinically significant results to determine the efficacy of BIT225.
However, an earlier point of yours is true. Given the success of Harvoni, and other recent approved treatments, is there any market for another successful drug? Good question.
